OMER Jan 2025 5.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.5500

-0.2000

(-26.67%)

At close: 03:57PM EDT

Loading interactive chart…

Thomson Reuters StreetEvents
Q1 2024 Omeros Corp Earnings Call
Q1 2024 Omeros Corp Earnings Call
GuruFocus.com
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
Business Wire
Omeros Corporation Reports First Quarter 2024 Financial Results
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include: